Prefrontal activity during working memory is modulated by the interaction of variation in CB1 and COX2 coding genes and correlates with frequency of cannabis use

Cortex

Volumn 81, Issue , 2016, Pages 231-238

  Taurisano, Paolo ^a,b   Antonucci, Linda A ^a   Fazio, Leonardo ^a,b   Rampino, Antonio ^a   Romano, Raffaella ^a   Porcelli, Annamaria ^a   Masellis, Rita ^a   Colizzi, Marco ^c   Quarto, Tiziana ^a,d   Torretta, Silvia ^a   Di Giorgio, Annabella ^b   Pergola, Giulio ^a   Bertolino, Alessandro ^a,e   Blasi, Giuseppe ^a  

^a UNIVERSITY OF BARI   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF HELSINKI   (Finland)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cannabis; CB1; COX2; DLPFC; Working memory

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABIS; CYCLOOXYGENASE 2; PTGS2 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; BOLD SIGNAL; CANNABIS USE; COGNITION; DORSOLATERAL PREFRONTAL CORTEX; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GENE EXPRESSION; GENETIC VARIATION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; SINGLE NUCLEOTIDE POLYMORPHISM; WORKING MEMORY; GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; PREFRONTAL CORTEX; PROCEDURES; SHORT TERM MEMORY; YOUNG ADULT;

ADULT; CANNABIS; CYCLOOXYGENASE 2; FEMALE; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY, SHORT-TERM; POLYMORPHISM, SINGLE NUCLEOTIDE; PREFRONTAL CORTEX; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 84971379284     PISSN: 00109452     EISSN: 19738102     Source Type: Journal    
DOI: 10.1016/j.cortex.2016.05.010     Document Type: Article

References (48)

1. Bertolino A., Blasi G. The genetics of schizophrenia. Neuroscience 2009, 164:288-299.
2. Bertolino A., Fazio L., Caforio G., Blasi G., Rampino A., Romano R., et al. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain: A Journal of Neurology 2009, 132:417-425.
3. Bertolino A., Fazio L., Di Giorgio A., Blasi G., Romano R., Taurisano P., et al. Genetically determined interaction between the dopamine transporter and the D2 receptor on prefronto-striatal activity and volume in humans. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2009, 29:1224-1234.
4. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Rizzini B.L., et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998, 391:281-285.
5. Bossong M.G., Jager G., van Hell H.H., Zuurman L., Jansma J.M., Mehta M.A., et al. Effects of Delta9-tetrahydrocannabinol administration on human encoding and recall memory function: a pharmacological FMRI study. Journal of Cognitive Neuroscience 2012, 24:588-599.
6. Bossong M.G., Jansma J.M., van Hell H.H., Jager G., Oudman E., Saliasi E., et al. Effects of delta9-tetrahydrocannabinol on human working memory function. Biological Psychiatry 2012, 71:693-699.
7. Callicott J.H., Egan M.F., Mattay V.S., Bertolino A., Bone A.D., Verchinksi B., et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. The American Journal of Psychiatry 2003, 160:709-719.
8. Callicott J.H., Mattay V.S., Bertolino A., Finn K., Coppola R., Frank J.A., et al. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cerebral Cortex 1999, 9:20-26.
9. Castner S.A., Goldman-Rakic P.S., Williams G.V. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology 2004, 174:111-125.
10. Chen C., Magee J.C., Bazan N.G. Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity. Journal of Neurophysiology 2002, 87:2851-2857.
11. Chen R., Zhang J., Fan N., Teng Z.Q., Wu Y., Yang H., et al. Delta9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling. Cell 2013, 155:1154-1165.
12. Cohen Kadosh K., Krause B., King A.J., Near J., Cohen Kadosh R. Linking GABA and glutamate levels to cognitive skill acquisition during development. Human Brain Mapping 2015, 36:4334-4345.
13. Colizzi M., Fazio L., Ferranti L., Porcelli A., Masellis R., Marvulli D., et al. Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2015, 40:640-649.
14. Colizzi M., McGuire P., Pertwee R.G., Bhattacharyya S. Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neuroscience and Biobehavioral Reviews 2016, 64:359-381.
15. Connor J.P., Gullo M.J., Feeney G.F., Young R.M. Validation of the Cannabis Expectancy Questionnaire (CEQ) in adult cannabis users in treatment. Drug and Alcohol Dependence 2011, 115:167-174.
16. D'Souza D.C., Fridberg D.J., Skosnik P.D., Williams A., Roach B., Singh N., et al. Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Delta(9)-THC in humans. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2012, 37:1632-1646.
17. Dave K.A., Platel J.C., Huang F., Tian D., Stamboulian-Platel S., Bordey A. Prostaglandin E2 induces glutamate release from subventricular zone astrocytes. Neuron Glia Biology 2010, 6:201-207.
18. Di Forti M., Morgan C., Dazzan P., Pariante C., Mondelli V., Marques T.R., et al. High-potency cannabis and the risk of psychosis. The British Journal of Psychiatry: The Journal of Mental Science 2009, 195:488-491.
19. Fan N., Yang H., Zhang J., Chen C. Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Delta9-THC exposure-impaired hippocampal synaptic plasticity. Journal of Neurochemistry 2010, 112:691-702.
20. Fazio L., Blasi G., Taurisano P., Papazacharias A., Romano R., Gelao B., et al. D2 receptor genotype and striatal dopamine signaling predict motor cortical activity and behavior in humans. NeuroImage 2011, 54:2915-2921.
21. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004, 174:3-16.
22. Gomez-Lira M., Ferronato S., Malerba G., Santinami M., Maurichi A., Sangalli A., et al. Association of promoter polymorphism -765G>C in the PTGS2 gene with malignant melanoma in Italian patients and its correlation to gene expression in dermal fibroblasts. Experimental Dermatology 2014, 23:766-768.
23. Han J., Kesner P., Metna-Laurent M., Duan T., Xu L., Georges F., et al. Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 2012, 148:1039-1050.
24. Hoffman A.F., Oz M., Yang R., Lichtman A.H., Lupica C.R. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learning & Memory 2007, 14:63-74.
25. Hollingshead A.B., Redlich F.C. Social class and mental illness 1958, Wiley, New York.
26. Jacobus J., Bava S., Cohen-Zion M., Mahmood O., Tapert S.F. Functional consequences of marijuana use in adolescents. Pharmacology, Biochemistry, and Behavior 2009, 92:559-565.
27. Lichtman A.H., Martin B.R. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 1996, 126:125-131.
28. Malone D.T., Hill M.N., Rubino T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. British Journal of Pharmacology 2010, 160:511-522.
29. Matsuda L.A. Molecular aspects of cannabinoid receptors. Critical Reviews in Neurobiology 1997, 11:143-166.
30. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
31. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. Journal of Neuropathology and Experimental Neurology 2004, 63:901-910.
32. Mouslech Z., Valla V. Endocannabinoid system: an overview of its potential in current medical practice. Neuro Endocrinology Letters 2009, 30:153-179.
33. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
34. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971, 9:97-113.
35. Papafili A., Hill M.R., Brull D.J., McAnulty R.J., Marshall R.P., Humphries S.E., et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arteriosclerosis, Thrombosis, and Vascular Biology 2002, 22:1631-1636.
36. Pazos M.R., Nunez E., Benito C., Tolon R.M., Romero J. Functional neuroanatomy of the endocannabinoid system. Pharmacology, Biochemistry, and Behavior 2005, 81:239-247.
37. Pergola G., Di Carlo P., Andriola I., Gelao B., Torretta S., Attrotto M.T., et al. Combined effect of genetic variants in the GluN2B coding gene (GRIN2B) on prefrontal function during working memory performance. Psychological Medicine 2016, 46:1135-1150.
38. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British Journal of Pharmacology 2008, 153:199-215.
39. Puighermanal E., Marsicano G., Busquets-Garcia A., Lutz B., Maldonado R., Ozaita A. Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nature Neuroscience 2009, 12:1152-1158.
40. Ruiz-Contreras A.E., Carrillo-Sanchez K., Gomez-Lopez N., Vadillo-Ortega F., Hernandez-Morales S., Carnevale-Cantoni A., et al. Working memory performance in young adults is associated to the AATn polymorphism of the CNR1 gene. Behavioural Brain Research 2013, 236:62-66.
41. Ruiz-Contreras A.E., Carrillo-Sanchez K., Ortega-Mora I., Barrera-Tlapa M.A., Roman-Lopez T.V., Rosas-Escobar C.B., et al. Performance in working memory and attentional control is associated with the rs2180619 SNP in the CNR1 gene. Genes, Brain, and Behavior 2014, 13:173-178.
42. Salthouse T.A., Atkinson T.M., Berish D.E. Executive functioning as a potential mediator of age-related cognitive decline in normal adults. Journal of Experimental Psychology. General 2003, 132:566-594.
43. Sang N., Zhang J., Marcheselli V., Bazan N.G., Chen C. Postsynaptically synthesized prostaglandin E2 (PGE2) modulates hippocampal synaptic transmission via a presynaptic PGE2 EP2 receptor. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2005, 25:9858-9870.
44. Sanzgiri R.P., Araque A., Haydon P.G. Prostaglandin E(2) stimulates glutamate receptor-dependent astrocyte neuromodulation in cultured hippocampal cells. Journal of Neurobiology 1999, 41:221-229.
45. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annual Review of Biochemistry 2000, 69:145-182.
46. van Winkel R., Kuepper R. Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis. Annual Review of Clinical Psychology 2014, 10:767-791.
47. Zhang J., Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. The Journal of Biological Chemistry 2008, 283:22601-22611.
48. Zhang Y., Bertolino A., Fazio L., Blasi G., Rampino A., Romano R., et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:20552-20557.